Form 4: Jazz Pharmaceuticals CEO Bruce Cozadd Acquires Shares Through Performance Award Vesting
SEC Form 4
Jazz Pharmaceuticals CEO Bruce Cozadd acquired 29,559 ordinary shares through the vesting of a performance share award, while 13,840 shares were withheld for tax obligations.
Summary
- Bruce Cozadd, CEO of Jazz Pharmaceuticals, acquired 29,559 ordinary shares on January 17, 2025, as part of a performance share award that vested.
- The performance-based vesting requirements for the award, granted on March 3, 2022, were met and certified on January 17, 2025.
- A total of 13,840 shares were withheld to cover tax obligations related to the vesting of the performance award.
- The shares withheld for taxes were valued at $122.62 each.
- Following these transactions, Mr. Cozadd directly owns 441,244 ordinary shares.
Sentiment
Score: 7
Explanation: The document reflects a positive event (vesting of performance shares) and increased share ownership by the CEO, which is generally viewed favorably by investors. However, it is a routine transaction and not a major catalyst.
Positives
- The vesting of performance shares indicates that performance goals were met, which is a positive sign for the company.
- The CEO's increased share ownership aligns his interests with those of other shareholders.
Industry Context
This type of transaction is common for executive compensation in publicly traded companies, where performance-based equity awards are used to align management's interests with those of shareholders.
Comparison to Industry Standards
- Performance-based equity awards are a standard practice in the pharmaceutical industry, with companies like Amgen, Gilead Sciences, and Biogen also using similar compensation structures.
- The vesting of these awards is typically tied to specific performance metrics, such as revenue growth, clinical trial milestones, or stock price appreciation, which is consistent with industry norms.
Stakeholder Impact
- Shareholders may view the vesting of performance shares positively as it indicates the achievement of performance goals.
- The increased share ownership by the CEO aligns his interests with those of other shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Date of the performance share award grant to Bruce Cozadd. |
| 01/17/2025 | Date the performance-based vesting requirements were satisfied and certified, and the shares were acquired. |
| 01/22/2025 | Date of signature of the form by attorney in fact. |
Keywords
Jazz Pharmaceuticals, Bruce Cozadd, performance share award, share vesting, executive compensation, insider trading, stock ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.